A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

Completed · Phase 1

Conditions studied: Myelogenous Leukemia, Acute

In brief

This Phase 1/1b, open-label study will evaluate the safety and pharmacokinetics of escalating doses of RO5503781 as a single agent or in combination with cytarabine in participants with acute myelogenous leukemia. In Part 1, RO5503781 will be administered in escalating doses as a single agent, and in Part 2, RO5503781 will be administered in combination with cytarabine. An optional Part 3 in which RO5503781 will be administered with cytarabine and anthracycline may be considered . In Part 4, the safety and pharmacokinetic profile of an optimized formulation of RO5503781 in combination with cytarabine will be assessed.

Key facts

Study ID

NCT01773408

Run by

Hoffmann-La Roche

People needed

122

Starts

2013-02-01

Expected to finish

2016-06-01

Last updated by the study team

2017-01-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented/confirmed acute myelogenous leukemia (AML), except for acute promyelocytic leukemia
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 in Part 1 and Part 2, participants enrolled in the extension/tail portion, Part 3 and Part 4 must have an ECOG performance status of 0 or 1
• All non-hematological adverse events of any prior chemotherapy, surgery or radiotherapy must have resolved to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade less than or equal to (</=) 2 prior to starting therapy
• Adequate hepatic and renal function
• Willing to submit the blood sampling and bone marrow sampling required by protocol
• Additional inclusion criteria for Parts 1-4 may apply.

You may not qualify if…

• Participants receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 14 days of first receipt of study drug, with the exception of hydroxyurea as defined in protocol
• History of allergic or toxic reactions attributed to cytarabine (Part 2) or history of allergic reactions to components of the formulated product
• Current evidence of central nervous system (CNS) leukemia
• Participants with severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
• Participants with evidence of electrolyte imbalance greater than or equal to (>/=) Grade 2 which cannot be corrected prior to study initiation
• Pregnant or breastfeeding women
• Human immunodeficiency virus (HIV) - positive participants receiving anti-retroviral therapy
• Participants who refuse to potentially receive blood products and/or have a hypersensitivity to blood products
• Additional exclusion criteria for Parts 1-4 may apply.

Where it is running

• USC Norris Cancer Center — Los Angeles, California, United States
• New York Medical College — Valhalla, New York, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• Cancer Therapy & Research Ctr; Dept Institute for Drug Development — San Antonio, Texas, United States
• Peter Maccallum Cancer Centre — Melbourne, Victoria, Australia
• University Health Network; Princess Margaret Hospital; Medical Oncology Dept — Toronto, Ontario, Canada
• McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology — Montreal, Quebec, Canada
• Institut J Paoli I Calmettes; Onco Hematologie 2 — Marseille, France
• Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpigh — Bologna, Emilia-Romagna, Italy
• Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology — Seoul, South Korea
• Asan Medical Center — Seoul, South Korea
• The Beatson West of Scotland Cancer Centre; Cancer Clinical Trials Unit — Glasgow, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.